Risk Adapted Treatment for Primary Acute Myeloid Leukemia (AML)

NCT01723657 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

862

Enrollment

OTHER

Sponsor class

Conditions

Leukemia, Myelocytic, Acute

Interventions

DRUG: Ara-C
OTHER: Autologous peripheral blood stem cell transplantation.
OTHER: Allogeneic matched related or unrelated donor transplant.
DRUG: G-CSF
OTHER: CD34+ selection.
OTHER: Mylotarg purging before autologous PBSC transplantation

Sponsor

Grupo Cooperativo de Estudio y Tratamiento de las Leucemias Agudas y Mielodisplasias